Company profile for Viracta Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Viracta is committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases. Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focus is on cancers associated with the Epstein Barr Virus (EBV). We will also expand into additional applications to utilize this approach for a range of cancers and viru...
Viracta is committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases. Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focus is on cancers associated with the Epstein Barr Virus (EBV). We will also expand into additional applications to utilize this approach for a range of cancers and virus-associated diseases. Our team possesses deep, cross-functional experience and longstanding commitment to develop new medicines to benefit patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2533 S. Coast Hwy 101, Suite 210, Cardiff, CA 92007
Telephone
Telephone
858-400-8470
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/02/05/3021635/0/en/Viracta-Therapeutics-Announces-Wind-Down-of-Operations.html

GLOBENEWSWIRE
05 Feb 2025

https://www.globenewswire.com/news-release/2024/12/26/3002051/0/en/Viracta-Therapeutics-Announces-Closure-of-NAVAL-1-Clinical-Trial-and-Exploration-of-Strategic-Alternatives.html

GLOBENEWSWIRE
26 Dec 2024

https://www.globenewswire.com/news-release/2024/11/13/2980086/0/en/Viracta-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
13 Nov 2024

https://www.biospace.com/job-trends/viracta-therapeutics-cuts-42-of-staff-as-part-of-resource-reprioritization

BIOSPACE
07 Nov 2024

https://www.globenewswire.com/news-release/2024/11/06/2976142/0/en/Viracta-Therapeutics-Announces-Reprioritization-of-Resources-to-Enhance-Focus-on-Nana-val-Development-Program-in-Patients-with-Relapsed-or-Refractory-EBV-Positive-Peripheral-T-Cell.html

GLOBENEWSWIRE
06 Nov 2024

https://www.globenewswire.com/news-release/2024/09/03/2939516/0/en/Viracta-Therapeutics-to-Present-at-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
03 Sep 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty